Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 23179 | 23.8101 |
09:34 ET | 2013 | 23.76 |
09:36 ET | 100 | 23.75 |
09:38 ET | 3445 | 23.9 |
09:39 ET | 3264 | 23.97 |
09:41 ET | 8800 | 24 |
09:43 ET | 13723 | 23.968 |
09:45 ET | 9521 | 24.025 |
09:48 ET | 13878 | 24.1219 |
09:50 ET | 5698 | 24.18 |
09:52 ET | 6370 | 24.155 |
09:54 ET | 13180 | 24.165 |
09:56 ET | 2835 | 24.17 |
09:57 ET | 10058 | 24.165 |
09:59 ET | 870 | 24.155 |
10:01 ET | 5459 | 24.13 |
10:03 ET | 8099 | 24.1751 |
10:06 ET | 6459 | 24.2037 |
10:08 ET | 11546 | 24.23 |
10:10 ET | 5175 | 24.23 |
10:12 ET | 7257 | 24.18 |
10:14 ET | 7146 | 24.12 |
10:15 ET | 2500 | 24.1376 |
10:17 ET | 4750 | 24.09 |
10:19 ET | 11365 | 24.12 |
10:21 ET | 4286 | 24.08 |
10:24 ET | 3400 | 24.08 |
10:26 ET | 3139 | 24.08 |
10:28 ET | 5208 | 24.13 |
10:30 ET | 4934 | 24.085 |
10:32 ET | 1782 | 24.11 |
10:33 ET | 2209 | 24.115 |
10:35 ET | 2075 | 24.1631 |
10:37 ET | 3750 | 24.18 |
10:39 ET | 3295 | 24.175 |
10:42 ET | 6145 | 24.2 |
10:44 ET | 5483 | 24.16 |
10:46 ET | 5806 | 24.17 |
10:48 ET | 2503 | 24.195 |
10:50 ET | 13586 | 24.23 |
10:51 ET | 2475 | 24.22 |
10:53 ET | 6071 | 24.21 |
10:55 ET | 3647 | 24.293858 |
10:57 ET | 3754 | 24.28 |
11:00 ET | 2800 | 24.25 |
11:02 ET | 800 | 24.255 |
11:04 ET | 9447 | 24.2999 |
11:06 ET | 9123 | 24.34 |
11:08 ET | 5475 | 24.4 |
11:09 ET | 8181 | 24.38 |
11:11 ET | 12802 | 24.24 |
11:13 ET | 2400 | 24.27 |
11:15 ET | 10549 | 24.28 |
11:18 ET | 10901 | 24.27 |
11:20 ET | 2000 | 24.26 |
11:22 ET | 3300 | 24.3 |
11:24 ET | 1402 | 24.28 |
11:26 ET | 2300 | 24.33 |
11:27 ET | 4607 | 24.28 |
11:29 ET | 2000 | 24.3088 |
11:31 ET | 1300 | 24.3 |
11:33 ET | 1250 | 24.28 |
11:36 ET | 2330 | 24.25 |
11:38 ET | 2600 | 24.21 |
11:40 ET | 4491 | 24.14 |
11:42 ET | 3495 | 24.08 |
11:44 ET | 11602 | 24.09 |
11:45 ET | 1402 | 24.09 |
11:47 ET | 12790 | 24.0213 |
11:49 ET | 6741 | 23.957 |
11:51 ET | 10988 | 23.91 |
11:54 ET | 3940 | 23.92 |
11:56 ET | 3800 | 23.932 |
11:58 ET | 41318 | 24.01 |
12:00 ET | 20140 | 24 |
12:02 ET | 2477 | 23.9 |
12:03 ET | 23427 | 23.87 |
12:05 ET | 2100 | 23.88 |
12:07 ET | 2281 | 23.86 |
12:09 ET | 9040 | 23.82 |
12:12 ET | 14682 | 23.7901 |
12:14 ET | 5956 | 23.74 |
12:16 ET | 11354 | 23.82 |
12:18 ET | 22338 | 23.76 |
12:20 ET | 3252 | 23.775 |
12:21 ET | 14672 | 23.66 |
12:23 ET | 1550 | 23.72 |
12:25 ET | 6320 | 23.73 |
12:27 ET | 1400 | 23.71 |
12:30 ET | 1700 | 23.73 |
12:32 ET | 3505 | 23.72 |
12:34 ET | 3308 | 23.71 |
12:36 ET | 1100 | 23.7062 |
12:38 ET | 2600 | 23.69 |
12:39 ET | 1700 | 23.67 |
12:41 ET | 13938 | 23.61 |
12:43 ET | 4888 | 23.565 |
12:45 ET | 1764 | 23.62 |
12:48 ET | 800 | 23.59 |
12:50 ET | 2000 | 23.6 |
12:52 ET | 1400 | 23.62 |
12:54 ET | 3715 | 23.62 |
12:56 ET | 600 | 23.5998 |
12:57 ET | 1651 | 23.605 |
12:59 ET | 2219 | 23.62 |
01:01 ET | 2200 | 23.58 |
01:03 ET | 1390 | 23.56 |
01:06 ET | 6835 | 23.58 |
01:08 ET | 5328 | 23.6 |
01:10 ET | 3904 | 23.62 |
01:12 ET | 2876 | 23.64 |
01:14 ET | 4628 | 23.63 |
01:15 ET | 700 | 23.62 |
01:17 ET | 4052 | 23.628 |
01:19 ET | 735 | 23.6479 |
01:21 ET | 5262 | 23.67 |
01:24 ET | 3102 | 23.695 |
01:26 ET | 9143 | 23.6901 |
01:28 ET | 17886 | 23.67 |
01:30 ET | 3119 | 23.65 |
01:32 ET | 11782 | 23.67 |
01:33 ET | 19667 | 23.69 |
01:35 ET | 3652 | 23.675 |
01:37 ET | 1534 | 23.673 |
01:39 ET | 3701 | 23.64 |
01:42 ET | 2063 | 23.6419 |
01:44 ET | 2658 | 23.66 |
01:46 ET | 800 | 23.67 |
01:48 ET | 3700 | 23.715 |
01:50 ET | 3774 | 23.7 |
01:51 ET | 2583 | 23.71 |
01:53 ET | 2300 | 23.74 |
01:55 ET | 1267 | 23.74 |
01:57 ET | 4490 | 23.69 |
02:00 ET | 1225 | 23.6995 |
02:02 ET | 1100 | 23.7 |
02:04 ET | 1884 | 23.68 |
02:06 ET | 733 | 23.69 |
02:08 ET | 4035 | 23.64 |
02:09 ET | 1792 | 23.65 |
02:11 ET | 3241 | 23.6429 |
02:13 ET | 4787 | 23.61 |
02:15 ET | 10105 | 23.57 |
02:18 ET | 4836 | 23.5801 |
02:20 ET | 16199 | 23.51 |
02:22 ET | 8124 | 23.445 |
02:24 ET | 10848 | 23.34 |
02:26 ET | 17878 | 23.3601 |
02:27 ET | 18757 | 23.4 |
02:29 ET | 5823 | 23.41 |
02:31 ET | 10849 | 23.43 |
02:33 ET | 1609 | 23.44 |
02:36 ET | 3357 | 23.45 |
02:38 ET | 2664 | 23.48 |
02:40 ET | 861 | 23.5 |
02:42 ET | 1133 | 23.53 |
02:44 ET | 63224 | 23.6 |
02:45 ET | 16541 | 23.615 |
02:47 ET | 5313 | 23.62 |
02:49 ET | 11484 | 23.635 |
02:51 ET | 4039 | 23.6 |
02:54 ET | 2814 | 23.58 |
02:56 ET | 2203 | 23.605 |
02:58 ET | 12666 | 23.5327 |
03:00 ET | 6548 | 23.54 |
03:02 ET | 4351 | 23.5 |
03:03 ET | 5492 | 23.535 |
03:05 ET | 3675 | 23.54 |
03:07 ET | 2400 | 23.53 |
03:09 ET | 7324 | 23.53 |
03:12 ET | 8557 | 23.4777 |
03:14 ET | 6241 | 23.385 |
03:16 ET | 4843 | 23.425 |
03:18 ET | 10923 | 23.43 |
03:20 ET | 6037 | 23.435 |
03:21 ET | 7719 | 23.43 |
03:23 ET | 1942 | 23.45 |
03:25 ET | 6978 | 23.4775 |
03:27 ET | 12964 | 23.53 |
03:30 ET | 5074 | 23.48 |
03:32 ET | 2969 | 23.48 |
03:34 ET | 5265 | 23.43 |
03:36 ET | 6701 | 23.42 |
03:38 ET | 3409 | 23.415 |
03:39 ET | 5045 | 23.415 |
03:41 ET | 6195 | 23.39 |
03:43 ET | 11147 | 23.4398 |
03:45 ET | 2000 | 23.4269 |
03:48 ET | 7446 | 23.39 |
03:50 ET | 10067 | 23.415 |
03:52 ET | 12664 | 23.45 |
03:54 ET | 15348 | 23.465 |
03:56 ET | 26693 | 23.445 |
03:57 ET | 21319 | 23.425 |
03:59 ET | 533634 | 23.39 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 3.7B | 39.0x | --- |
ADMA Biologics Inc | 4.2B | 142.2x | --- |
Twist Bioscience Corp | 2.8B | -11.8x | --- |
Arrowhead Pharmaceuticals Inc | 2.7B | -4.2x | --- |
Axsome Therapeutics Inc | 4.5B | -13.8x | --- |
Arcellx Inc | 4.1B | -79.4x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7B |
---|---|
Revenue (TTM) | $346.7M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.21 |
EPS | $0.60 |
Book Value | $1.06 |
P/E Ratio | 39.0x |
Price/Sales (TTM) | 10.6 |
Price/Cash Flow (TTM) | 38.3x |
Operating Margin | 29.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.